vorasidenib
servier
['vorasidenib']
in patients with gliomas bearing idh1/2 mutations, the brain barrier-crossing oral drug vorasidenib kept tumors at bay, and could be used instead of more toxic chemotherapies and radiation. #asco23 
Medscape provides breaking medical news and expert perspectives, drug and disease information, and free CME across 30+ medical specialties.